Sugi Predict

Sugi Predict / Compounds / SCHEMBL21496580

SCHEMBL21496580

SCHEMBL21496580

[2H]C([2H])([2H])N1C(=O)[C@@H](NC(=O)OC(C)(C)C)COc2cccnc21

nearest known ligand 0.49

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 18/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19207688 0.93 RIPK1 (0.56) RIPK1
SCHEMBL29014311 0.93 RIPK1 (0.56) RIPK1
SCHEMBL22736912 0.86 RIPK1 (0.47) RIPK1
SCHEMBL19207590 0.85 RIPK1 (0.57) RIPK1
SCHEMBL22953697 0.84 RIPK1 (0.43) RIPK1
SCHEMBL19207895 0.81 RIPK1 (0.50) RIPK1
SCHEMBL23337280 0.78 RIPK1 (0.42) RIPK1
SCHEMBL23337279 0.78 RIPK1 (0.42) RIPK1
SCHEMBL23335759 0.78 KDM4D (0.43) RIPK1
SCHEMBL23335755 0.78 KDM4D (0.43) RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388601-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2025-12-25 — — US disclosed
US-12358928-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2025-07-15 — — US disclosed
US-20240150376-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2024-05-09 — — US disclosed
EP-3781571-B1 N-[4-OXO-2,3-DIHYDRO-PYRIDO[3,2-B][1,4]OXAZEPIN-3-YL]-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOLE-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RIP1 KINASE INHIBITORS FOR TREATING E.G. IRRITABLE BOWEL SYNDROME (IBS) HOFFMANN LA ROCHE (CH) 2024-01-17 — — EP disclosed
US-11634436-B2 Pyridine lactam compounds and methods of use thereof GENENTECH, INC. (US) 2023-04-25 — — US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 — — US disclosed
EP-3781571-A1 N-[4-OXO-2,3-DIHYDRO-1,5-BENZOXAZEPIN-3-YL]-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOL E-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RIP1 KINASE INHIBITORS FOR TREATING E.G. IRRITABLE BOWEL SYNDROME (IBS) F. Hoffmann-La Roche AG (CH) 2021-02-24 — — EP disclosed
WO-2019204537-A1 N-[4-OXO-2,3-DIHYDRO-1,5-BENZOXAZEPIN-3-YL]-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOL E-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RIP1 KINASE INHIBITORS FOR TREATING E.G. IRRITABLE BOWEL SYNDROME (IBS) GENENTECH, INC. (US) 2019-10-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388601-A1 Compounds, Compositions and Methods AURKC, WEE2, ERBB2 RIPK1 1507/4885
US-20240150376-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB RIPK1 416/4885
US-12358928-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB RIPK1 416/4885
US-20230043400-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB RIPK1 416/4885
US-11634436-B2 Pyridine lactam compounds and methods of use thereof RB1, RBX1, RPSA RIPK1 1875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.